107 related articles for article (PubMed ID: 26900813)
1. T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy.
Choi M; Fink S; Prasad V; Anagnostopoulos I; Reinke P; Schmitt CA
Transplantation; 2016 Mar; 100(3):e8-e10. PubMed ID: 26900813
[No Abstract] [Full Text] [Related]
2. First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis.
Schaefer B; Steurer M; Glodny B; Neureiter D; Moser P; Dorn L; Vogel W; Zoller H
Liver Transpl; 2014 Sep; 20(9):1145-8. PubMed ID: 24844674
[No Abstract] [Full Text] [Related]
3. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
4. CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.
Theurich S; Wennhold K; Wedemeyer I; Rothe A; Hübel K; Shimabukuro-Vornhagen A; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
Transplantation; 2013 Aug; 96(3):e16-8. PubMed ID: 23917689
[No Abstract] [Full Text] [Related]
5. Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy.
Patsinakidis N; Kreuter A; Moritz RK; Stücker M; Altmeyer P; Möllenhoff K
Acta Derm Venereol; 2015 Feb; 95(2):233-4. PubMed ID: 24733422
[No Abstract] [Full Text] [Related]
6. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma.
Younes A
Hematol Oncol Clin North Am; 2014 Feb; 28(1):27-32. PubMed ID: 24287065
[TBL] [Abstract][Full Text] [Related]
9. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
10. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
11. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.
Theurich S; Malcher J; Wennhold K; Shimabukuro-Vornhagen A; Chemnitz J; Holtick U; Krause A; Kobe C; Kahraman D; Engert A; Scheid C; Chakupurakal G; Hallek M; von Bergwelt-Baildon M
J Clin Oncol; 2013 Feb; 31(5):e59-63. PubMed ID: 23269992
[No Abstract] [Full Text] [Related]
13. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999
[No Abstract] [Full Text] [Related]
14. Brentuximab vedotin in anaplastic large cell lymphoma.
Skarbnik AP; Smith MR
Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
16. Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients.
Monjanel H; Deville L; Ram-Wolff C; Venon MD; Franchi P; Benet C; de Kerviler E; Malphettes M; Thieblemont C; Brice P
Br J Haematol; 2014 Jul; 166(2):306-8. PubMed ID: 24673542
[No Abstract] [Full Text] [Related]
17. Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Broccoli A; Pellegrini C; Celli M; Argnani L; Agostinelli C; Pileri S; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):e119-22. PubMed ID: 24629851
[No Abstract] [Full Text] [Related]
18. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
19. Remission of primary cutaneous anaplastic large cell lymphoma after a brief course of brentuximab vedotin.
Desai A; Telang GH; Olszewski AJ
Ann Hematol; 2013 Apr; 92(4):567-8. PubMed ID: 23086510
[No Abstract] [Full Text] [Related]
20. Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
Illés Á; Jóna Á; Miltényi Z
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):451-9. PubMed ID: 25642958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]